Skip to main content

Table 4 Short-term efficacy of exploratory therapy

From: Olaparib in the therapy of advanced ovarian cancer: first real world experiences in safety and efficacy from China

Short-term efficacyNumber of patients (Percent)
Complete response (CR)2 (20.0)
Partial response (PR)0 (0)
Stable disease (SD)3 (30.0)
Progressive disease (PD)5 (50.0)
  1. Short-term efficacy was classified by modified Response Evaluation Criteria in Solid Tumors version 1.1(RECIST 1.1)